System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Marcus A Mall is an expert in Pulmonology at Charité - University Medicine Berlin (Germany). As of October 2026, ScienceLeadR ranks Marcus A Mall in the top 1% of experts worldwide for Cystic Fibrosis, Pancreatic Diseases and Bronchiectasis. Marcus A Mall has authored 585 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 5 of them ongoing. SLR score: 2,689 (community average: 125). How the SLR is computed.

LeadR Profile

Marcus A Mall Charité - University Medicine Berlin Germany
2 689 ScienceLeadR Reputation 2689

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Nephrology - Pediatrics - Critical Care

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Charité - University Medicine Berlin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 585

Citations

Citations: 19 340 1st author: 20 Last author: 165 Unique author: 5

Main journals

J Cyst Fibros 134
Am J Respir Crit Care Med 41
Eur Respir J 35
Pneumologie 25
Klin Padiatr 19

Best Journals

Lancet Respir Med 7
N Engl J Med 5
Am J Respir Crit Care Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Effect of telemonitoring on adherence to inhalation therapy and pulmonary exacerbations in people with cystic fibrosis (conneCT CF): a multicenter randomized controlled trial.
PMID 42949105 — fibrosis, telemedicine, inhalation, cystic fibrosis, mentoring, therapeutics		Ann Am Thorac Soc20260
Long-term safety and efficacy of lumacaftor/ivacaftor in children aged ≥12 months of age with cystic fibrosis: a 96-week open-label study.
PMID 42935985 — safety, fibrosis, aged, drug-related side effects and adverse reactions, cystic fibrosis, therapeutics, child		ERJ Open Res20260
Conditionally Reprogrammed Patient-Derived Nasal Epithelial Cell Cultures for In Vitro Diagnostics and Pharmacological Profiling in Primary Ciliary Dyskinesia.
PMID 42929845 — cells, dyskinesias, diagnostic techniques and procedures, ciliary motility disorders, epithelial cells, cilia, clenbuterol, precision medicine, kartagener syndrome, cell culture techniques		Cells20260
Longitudinal Functional Magnetic Resonance Imaging to Assess Lung Disease in Cystic Fibrosis.
PMID 42858172 — lung, fibrosis, magnetic resonance imaging, cystic fibrosis, lung diseases, ventilation		Ann Am Thorac Soc20261
Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells.
PMID 42829305 — colforsin, cells, epithelial cells, cystic fibrosis, alleles, therapeutics, pharmaceutical vehicles		J Cyst Fibros20260

Clinical Studies 30

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 18
Phase 2 7
N/A 4
Phase 1/Phase 2 1

By status:

Completed 21
Active not recruiting 4
Recruiting 3
Terminated 1
Unknown 1

By type:

Interventional 26
Observational 4

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 4
multicentric5to9 3
multicentricup10 22

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Clairleaf TM A study to test long term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this medicine
2023-503290-38-00 — safety, therapeutics, bronchiectasis		Phase 2Active not recruiting2023
The AIRTIVITY TM Study A study to find out whether BI 1291583 helps people with bronchiectasis
2024-518589-29-00 — safety, bronchiectasis		Phase 3Active not recruiting2025
Evaluation of Long term Safety and Efficacy of ELX TEZ IVA in Cystic Fibrosis Subjects 12 Months of Age and Older
2023-509563-24-00 — safety, fibrosis, cystic fibrosis		Phase 3Active not recruiting2025
The AIRTIVITY Study A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892 — safety, tablets, bronchiectasis		Phase 3Recruiting2025
Evaluation of VX 121 Tezacaftor Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT05422222 — administration, oral, safety, fibrosis, cytidine triphosphate, cystic fibrosis, therapeutics, pharmacokinetics		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS